PRESS RELEASE published on 06/13/2025 at 01:25, 1 year ago Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Moderna receives FDA approval to expand indication of mRESVIA vaccine for adults aged 18-59 at increased risk of RSV, based on Phase 3 study results showing safety and efficacy FDA Approval Moderna RSV Vaccine Phase 3 Study MRESVIA
BRIEF published on 06/11/2025 at 13:05, 1 year ago Moderna to Present at Barclays Science Call Series MRNA Technology Presentation Moderna Barclays Investor Event
BRIEF published on 06/11/2025 at 13:05, 1 year ago Moderna participera à la série d'appels scientifiques de Barclays Presentation Barclays Moderne Événement Pour Les Investisseurs Technologie De L'ARNm
PRESS RELEASE published on 06/11/2025 at 13:00, 1 year ago Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 Moderna, Inc. announces participation in Barclays Speaking the Science Call Series on June 16th at 10:00am ET. Webcast available on Moderna's website Webcast MRNA Medicine Moderna Barclays Investor Event
BRIEF published on 05/31/2025 at 06:21, 1 year ago Moderna's mNEXSPIKE COVID-19 Vaccine Secures FDA Approval FDA Approval COVID-19 Vaccine Clinical Trial Moderna MNEXSPIKE
BRIEF published on 05/31/2025 at 06:21, 1 year ago Le vaccin mNEXSPIKE de Moderna contre la COVID-19 obtient l'approbation de la FDA Essai Clinique Approbation De La FDA Moderne Vaccin Contre Le Covid-19 MNEXSPIKE
PRESS RELEASE published on 05/31/2025 at 06:16, 1 year ago Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE Moderna's mNEXSPIKE, a new COVID-19 vaccine, receives FDA approval for high-risk age groups. The vaccine shows higher efficacy compared to the original mRNA-1273. Safety profile similar to Spikevax FDA Approval COVID-19 Vaccine Moderna Efficacy MNEXSPIKE
BRIEF published on 05/29/2025 at 00:05, 1 year ago Moderna Reports Progress and Setback in Avian Flu Vaccine Program Moderna Vaccine Development Phase 1/2 Study H5 Avian Flu MRNA-1018
BRIEF published on 05/29/2025 at 00:05, 1 year ago Moderna fait état de progrès et de revers dans son programme de vaccination contre la grippe aviaire Développement De Vaccins Moderne Étude De Phase 1/2 Grippe Aviaire H5 ARNm-1018
PRESS RELEASE published on 05/29/2025 at 00:00, 1 year ago Moderna Announces Update on Investigational Pandemic Influenza Program Moderna's Phase 1/2 H5 avian flu vaccine study shows positive interim results with robust immune response. HHS terminates late-stage development award Moderna Phase 1/2 Study Avian Flu Vaccine H5 Subtype HHS Termination
Published on 06/20/2026 at 01:00, 1 day 7 hours ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 8 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 3 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 7 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 7 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 11 hours 3 minutes ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 2 hours ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 12 hours ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 1 day 12 hours ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 1 day 13 hours ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 1 day 12 hours ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 1 day 12 hours ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 1 day 13 hours ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 1 day 13 hours ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
